Serotonergic mechanisms involved in calcitonin potentiation of κ-opioid receptor-mediated effects on adrenal secretion

European Journal of Pharmacology

Volumn 340, Issue 1, 1997, Pages 81-87

  Ormazábal, María J ^b   Milanés, M Victoria ^a   Martín, M Isabel ^b  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Opioid receptor; Calcitonin, 5 HT (5 hydroxytryptamine, serotonin) turnover; Corticosterone release; Hypothalamic pituitary adrenal axis

Indexed keywords

3 HYDROXYBENZYLHYDRAZINE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; CALCITONIN; CORTICOSTERONE; KAPPA OPIATE RECEPTOR; OPIATE; TRANYLCYPROMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; SEROTONIN METABOLISM; SEROTONINERGIC SYSTEM;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; 5-HYDROXYTRYPTOPHAN; ANALGESICS, NON-NARCOTIC; ANIMALS; CALCITONIN; CORTICOSTERONE; DOPA DECARBOXYLASE; ENZYME INHIBITORS; HYDRAZINES; HYDROXYINDOLEACETIC ACID; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MONOAMINE OXIDASE INHIBITORS; PITUITARY-ADRENAL SYSTEM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; SEROTONIN; TRANYLCYPROMINE;

EID: 17344384789     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01355-1     Document Type: Article

References (40)

1. Alcaraz C., Milanés M.V., Vargas M.L. Chronic kappa opioid receptor antagonism produces supersensitivity to U-50,488H at the hypothalamo-pituitary-adrenocortical (HPA) axis level. J. Pharmacol. Exp. Ther. 266:1993;1385-1389.
2. Alcaraz C., Vargas M.L., Fuente T., Milanés M.V. Chronic naloxone treatment induces supersensitivity to a mu but not to a kappa agonist at the hypothalamus-pituitary-adrenocortical level. J. Pharmacol. Exp. Ther. 266:1993;1602-1606.
3. Beaudet A., Descarries L. Radiographic characterization of a serotonin-accumulating nerve cell group in adult rat hypothalamus. Brain Res. 160:1979;231-243.
4. 3H ]5-hydroxytryptamine release from the rat spinal cord Eur. J. Pharmacol. 156:1988;13-23.
5. Buckingham J.C., Cooper T.A. Differences in hypothalamus-pituitary-adrenocortical activity in the rat after acute and prolonged treatment with morphine. Neuroendocrinology. 38:1984;411-417.
6. Carlsson A., Davis J.N., Kehr W., Lindquist M., Atack C.V. Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of aromatic amino acid decarboxylase. Naunyn Schmiedebergs Arch. Pharmacol. 275:1972;153-168.
7. Clementi G., Nicoletti F., Patacchioli F., Prato A., Patti F., Fiore C.E., Matera M., Scapagnini U. Hypoprolactinemic action of calcitonin and the tuberoinfundibular dopaminergic system. J. Neurochem. 40:1983;885-886.
8. Clementi G., Drago F., Prato A., Cavaliere S., Di Benedetto A., Leone F., Scapagnini U., Rodolico G. Effects of calcitonin, parathyroid hormone and its related fragments on acquisition of active avoidance behaviour. Physiol. Behav. 33:1984;913-916.
9. Clementi G., Prato A., Conforto G., Scapagnini U. Role of serotonin in the analgesic activity of calcitonin. Eur. J. Pharmacol. 98:1984;449-451.
10. Clementi G., Amico-Roxas M., Rasiparda E., Caruso A., Prato A., Trombadore S., Priolo G., Scapagnini U. The analgesic activity of calcitonin and the central serotonergic system. Eur. J. Pharmacol. 108:1985;71-75.
11. Clementi G., Valerio C., Prato A., Caruso A., Patti F., Patane A., Drago F. Effects of calcitonin on morphine tolerance and withdrawal syndrome in morphine physically dependent rats. Eur. J. Pharmacol. 163:1989;175-179.
12. Colado M.I., Ormazábal M.J., Goicoechea C., López F., Alfaro M.J., Martín M.I. Involvement of central serotonergic pathways in analgesia elicited by salmon calcitonin in the mouse. Eur. J. Pharmacol. 252:1994;291-297.
13. 5]enkephalin-like material from the rat spinal cord. Eur. J. Pharmacol. 168:1989;201-208.
14. Cooper C.W., Obie J.F., Toverud S.U., Munson P.L. Elevated serum calcitonin during suckling in the baby rat. Endocrinology. 101:1977;1657-1664.
15. Goltzman D., Mitchell J. Interaction of calcitonin and calcitonin gene-related peptide at receptor sites in target tissues. Science. 227:1985;1343-1345.
16. Gonzálvez M.L., Milanés M.V., Vargas M.L. Effects of acute and chronic administration of μ- and κ-opioid agonists on hypothalamus-pituitary-adrenocortical (HPA) axis in the rat. Eur. J. Pharmacol. 200:1991;155-158.
17. Green A.R., De Souza R.J., Williams J.L., Murray T.K., Cross A.J. The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: Evidence for the protective effect of chlormethiazole. Neuropharmacology. 31:1992;315-321.
18. Kent D.L., Sladek J.R. Histochemical, pharmacological and microspectrofluorometric analysis of new sites of serotonin localization in the rat hypothalamus. J. Comp. Neurol. 180:1978;221-236.
19. Laurian L., Oberman Z., Graf E., Gilad S., Hoerer E., Simantov R. Calcitonin induced increase in ACTH, β-endorphin and cortisol secretion. Horm. Metabol. Res. 18:1986;268-271.
20. Mansour A., Fox C.A., Akil H., Watson S.J. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications. TINS. 18:1995;22-29.
21. Marshall I., Grahame-Smith D.G. Evidence against a role of brain 5-hydroxytryptamine in the development of physical dependence upon morphine in mice. J. Pharmacol. Exp. Ther. 179:1971;634-641.
22. Martín M.I., Goicoechea C., Colado M.I., Alfaro M.J. Analgesic effect of salmon-calcitonin administered by two routes. Effect on morphine analgesia. Eur. J. Pharmacol. 224:1992;77-82.
23. Martín M.I., Alfaro M.J., Goicoechea C., Colado M.I. In vitro study of the interaction of salmon calcitonin with μ, δ and κ opioid agonists. Naunyn-Schmiedebergs Arch. Pharmacol. 347:1993;324-328.
24. Martín M.I., Goicoechea C., Ormazábal M.J., Alfaro M.J. Influence of pertussis toxin on the calcitonin-opioid interaction in isolated tissues. Br. J. Pharmacol. 119:1996;804-806.
25. Martínez J.A., Vargas M.L., Fuente T., del Rio-García J., Milanés M.V. Plasma β-endorphin and cortisol levels in morphine-tolerant rats and in naloxone-induced withdrawal. Eur. J. Pharmacol. 182:1990;117-123.
26. Milanés M.V., Gonzálvez M.L., Fuente T., Vargas M.L. Pituitary-adrenocortical response to acute and chronic administration of U-50,488H in the rat. Neuropeptides. 20:1991;95-102.
27. Milanés M.V., Vargas M.L., Martín M.I. Involvement of κ-opioid receptor mechanisms in the calcitonin-induced potentiation of opioid effects at the hypothalamus-pituitary-adrenocortical axis. Eur. J. Pharmacol. 271:1993;103-109.
28. Oberman Z., Graff E., Chayen R., Grazas N., Burstein A., Laurian L. Dexamethasone suppression of the calcitonin induced beta-endorphin, ACTH and cortisol secretion. J. Neural Transm. Gen. Sect. 87:1992;125-131.
29. Olgiati V.R., Guidobono F., Netti C., Pecile A. Localization of calcitonin binding sites in rat central nervous system: Evidence of its neuroactivity. Brain Res. 265:1983;209-215.
30. Owens M.J., Nemeroff C.B. Physiology and Pharmacology of corticotropin releasing factor. Pharmacol. Rev. 43:1991;425-473.
31. Pechnick R.N. Effects of opioids on the hypothalamo-pituitary-adrenal axis. Annu. Rev. Pharmacol. Toxicol. 33:1993;353-382.
32. 2+-antagonist nimodipine on dopamine metabolism in mouse brain. J. Neural. Transm. 66:1986;171-187.
33. Sawchenko P.E., Swanson L.W., Steinbusch H.W.M., Verhofstad A.A.J. The distribution and cells of origin of serotonergic inputs to the paraventricular and supraoptic nuclei of the rat. Brain Res. 277:1983;355-360.
34. Simerly R.B., Swanson L.W., Gorski R.A. Demonstration of a sexual dimorphism in the distribution of serotonin-immunoreactive fibers in the medial preoptic nucleus of the rat. J. Comp. Neur. 225:1984;151-166.
35. Spampinato S., Candeletti S., Cavicchini E., Romualdi P., Speroni E., Ferri S. Antinociceptive activity of salmon calcitonin injected intrathecally in the rat. Neurosci. Lett. 45:1984;135-139.
36. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. Suppl. 367:1971;1-48.
37. Ustdal M., Dogan P., Soyuer A., Terzi S. Treatment of migraine with salmon calcitonin: Effects on plasma beta-endorphin, ACTH and cortisol levels. Biomed. Pharmacother. 43:1989;687-691.
38. Vescovi P.P., Pedrazzoni M., Gerra G., Maninetti L., Michelini M., Pioli G., Passeri M. Salmon calcitonin given by nasal spray or by injection does not increase beta-endorphin levels in normal men. Life Sci. 47:1990;1469-1473.
39. Von Voigtlander P.F., Lahti R.A., Ludens J.H. U-50,488H: A selective and structurally novel non-mu (kappa) opioid agonist. J. Pharmacol. Exp. Ther. 224:1983;7-12.
40. Welch S.P., Dewey W.L. The activity of several peptide fragments of parathyroid hormone, alone and in combination with salmon calcitonin and morphine, in antinociceptive tests in the mouse. J. Pharmacol. Exp. Ther. 252:1990;140-146.